Cytosorbents CORP (CTSO) — SEC Filings

Overview

Cytosorbents CORP (CTSO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: Cytosorbents Corp (CTSO) reported a focus on its proprietary blood purification technologies, particularly CytoSorb and the investigational DrugSorb-ATR. CytoSorb, approved in the EU and distributed in over 70 countries with more than 300,000 devices used, targets severe inflammation and toxin remov

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bullish, 5 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Cytosorbents CORP is neutral.

Filing Type Overview

Cytosorbents CORP (CTSO) has filed 38 8-K, 3 10-K, 6 10-Q, 2 DEF 14A, 1 SC 13G/A with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 8-K Filing — 8-K · Apr 2, 2026
• Cytosorbents Pushes US Approval for Blood Thinner Reversal Device — 10-K · Mar 30, 2026 Risk: high
  Cytosorbents Corp (CTSO) reported a focus on its proprietary blood purification technologies, particularly CytoSorb and the investigational DrugSorb-ATR. CytoSo
• Cytosorbents Narrows 9-Month Loss to $2.7M on Revenue Growth — 10-Q · Nov 13, 2025 Risk: high
  Cytosorbents Corp (CTSO) reported a net loss of $3.17 million for the three months ended September 30, 2025, a slight increase from the $2.77 million net loss i
• 8-K Filing — 8-K · Nov 13, 2025
• Cytosorbents Corp Faces Delisting Concerns — 8-K · Oct 3, 2025 Risk: high
  Cytosorbents Corporation filed an 8-K on October 3, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a tran
• Cytosorbents Corp. Files 8-K with Regulatory Updates — 8-K · Sep 16, 2025 Risk: low
  Cytosorbents Corp. filed an 8-K on September 16, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other
• Cytosorbents Corp Files 8-K on Other Events — 8-K · Aug 20, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on August 20, 2025, reporting an event that occurred on August 14, 2025. The filing pertains to 'Other Events' and 'Financ
• Cytosorbents' Q2 Loss Widens to $7.5M Amid Revenue Dip — 10-Q · Aug 7, 2025 Risk: high
  Cytosorbents Corp reported a net loss of $7.5 million for the three months ended June 30, 2025, a significant increase from the $5.2 million net loss in the pri
• Cytosorbents Corp. Completes Asset Acquisition/Disposition — 8-K · Aug 7, 2025 Risk: medium
  Cytosorbents Corp. announced on August 7, 2025, the completion of an acquisition or disposition of assets. The filing does not specify the nature of the transac
• Cytosorbents Corp Files 8-K — 8-K · Aug 1, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on July 31, 2025, reporting other events and financial statements. The filing details the company's corporate structure, i
• Cytosorbents Corp Files 8-K — 8-K · Jul 2, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on July 2, 2025, reporting other events and financial statements. The filing does not contain specific details about the n
• Cytosorbents Corp Files 8-K — 8-K · Jun 24, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on June 24, 2025, reporting other events and financial statements. The filing does not contain specific details on new eve
• Cytosorbents Corp Files 8-K on Security Holder Vote — 8-K · Jun 13, 2025 Risk: low
  Cytosorbents Corporation announced on June 12, 2025, that it is submitting matters to a vote of its security holders. The company, incorporated in Delaware with
• Cytosorbents Corp Files 8-K: Regulation FD Disclosure — 8-K · Jun 11, 2025 Risk: low
  Cytosorbents Corporation announced on June 10, 2025, a Regulation FD Disclosure. The filing does not contain specific financial figures or new material events b
• Cytosorbents Corp Files 8-K on Operations and Financials — 8-K · May 14, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhib
• Cytosorbents Corp Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Cytosorbents Corporation filed a 10-Q for the period ending March 31, 2025. The company, formerly known as MedaSorb Technologies CORP, is based in Princeton, NJ
• Cytosorbents Corp Files 8-K with Financials — 8-K · May 1, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on May 1, 2025, reporting events as of April 25, 2025. The filing primarily concerns financial statements and exhibits, wi
• Cytosorbents Files Definitive Proxy Statement for June Meeting — DEF 14A · Apr 23, 2025 Risk: low
  Cytosorbents Corporation filed its definitive proxy statement (DEF 14A) on April 23, 2025, for its annual meeting on June 12, 2025. The filing concerns the soli
• Cytosorbents Corp Files 8-K — 8-K · Apr 17, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on April 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Cytosorbents Corp Files 8-K — 8-K · Apr 15, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on April 15, 2025, reporting an event on April 14, 2025. The filing is categorized under Regulation FD Disclosure and Fina
• Cytosorbents Corp Files 8-K: Other Events & Financials — 8-K · Apr 4, 2025 Risk: low
  On April 4, 2025, Cytosorbents Corporation filed an 8-K report detailing other events and financial statements. The company, formerly known as MedaSorb Technolo
• Cytosorbents Corp. Withdraws Prior Financial Statements — 8-K · Mar 31, 2025 Risk: high
  Cytosorbents Corporation announced on March 25, 2025, that it will not rely on previously issued financial statements. This decision impacts financial reporting
• Cytosorbents Corp Files 2024 Annual Report — 10-K · Mar 31, 2025 Risk: medium
  Cytosorbents Corporation filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as MedaSorb Technologies CORP and GILDER ENTER
• Cytosorbents Corp Files 8-K on Financials — 8-K · Mar 21, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on March 21, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• Cytosorbents Corp Files 8-K on Financials — 8-K · Mar 4, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on March 4, 2025, reporting on its results of operations and financial condition, as well as providing Regulation FD discl
• Cytosorbents Corp Files 8-K — 8-K · Feb 25, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on February 25, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
• Cytosorbents Corp Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation F
• Cytosorbents Corp Files 8-K — 8-K · Jan 6, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on January 6, 2025, reporting other events and financial statements. The filing indicates a change in the company's status
• Cytosorbents Corp Files 8-K on Financials — 8-K · Jan 3, 2025 Risk: low
  Cytosorbents Corporation filed an 8-K on January 3, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• Cytosorbents Corp Files 8-K — 8-K · Dec 23, 2024 Risk: low
  Cytosorbents Corporation filed an 8-K on December 23, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
• Cytosorbents to be Acquired by Fresenius Medical Care for $107M — 8-K · Dec 9, 2024 Risk: medium
  Cytosorbents Corporation announced on December 9, 2024, that it has entered into a definitive agreement to be acquired by Fresenius Medical Care AG & Co. KGaA f
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Cytosorbents Corp Files 8-K on Financials — 8-K · Nov 7, 2024 Risk: low
  Cytosorbents Corporation filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, as well as financial statements and e
• Cytosorbents Corp Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Cytosorbents Corp filed a 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business operations.
• Cytosorbents Corp Files 8-K on Operations and Financials — 8-K · Oct 1, 2024 Risk: low
  Cytosorbents Corporation filed an 8-K on October 1, 2024, reporting on its results of operations and financial condition, as well as other events. The filing al
• Cytosorbents Corp Enters Material Definitive Agreement — 8-K · Aug 20, 2024 Risk: medium
  Cytosorbents Corporation entered into a Material Definitive Agreement on August 16, 2024. The filing does not disclose specific details of the agreement, such a
• Cytosorbents Appoints New CMO, Elects Director — 8-K · Aug 16, 2024 Risk: low
  Cytosorbents Corporation announced on August 13, 2024, the appointment of Dr. Phillip P. Chan as Chief Medical Officer and the election of Ms. Amy E. Smith to i
• Cytosorbents Corp Files 8-K on Financials — 8-K · Aug 14, 2024 Risk: low
  Cytosorbents Corporation filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition as of August 13, 2024. The filing detai
• Cytosorbents Corp Q2 2024 Update: Revenue and Cash Position — 10-Q · Aug 13, 2024 Risk: medium
  Cytosorbents Corp filed its 10-Q for the period ending June 30, 2024. The company reported $8.46 million in revenue for the six months ended June 30, 2024. Key
• Cytosorbents Sells STARZ Business for Up to $100M — 8-K · Aug 1, 2024 Risk: medium
  Cytosorbents Corporation announced on July 26, 2024, that it has entered into a definitive agreement to sell its STARZ medical device business to an affiliate o
• Cytosorbents Corp Files 8-K: Material Agreement & Other Events — 8-K · Jul 5, 2024 Risk: medium
  Cytosorbents Corporation entered into a Material Definitive Agreement on June 28, 2024, related to its business operations. The filing also includes other event
• Cytosorbents Sets 2024 Annual Meeting Date — 8-K · Jun 10, 2024 Risk: low
  Cytosorbents Corporation announced on June 6, 2024, that it has scheduled its 2024 Annual Meeting of Stockholders for July 18, 2024. The meeting will include th
• Cytosorbents Delists from Nasdaq, Moves to OTCQB — 8-K · May 22, 2024 Risk: high
  Cytosorbents Corporation filed an 8-K on May 22, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company's
• Cytosorbents Corp Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
  Cytosorbents Corporation filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition, and including financial statements and exh
• Cytosorbents Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  Cytosorbents Corp (CTSO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Cytosorbents Corp reported total assets of $54.29M and total debt of $0 fo
• Cytosorbents Corp Files 8-K for Bylaw Amendments & Financials — 8-K · May 6, 2024 Risk: low
  Cytosorbents Corporation filed an 8-K on May 2, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, inc
• CytoSorbents Corporation Announces Virtual Annual Meeting of Stockholders on June 6, 2024 — DEF 14A · Apr 19, 2024 Risk: low
  Cytosorbents Corp (CTSO) filed a Proxy Statement (DEF 14A) with the SEC on April 19, 2024. The Annual Meeting of CytoSorbents Corporation stockholders will be h
• Cytosorbents Appoints Dr. Vincent P. Cappello as CMO — 8-K · Apr 3, 2024 Risk: low
  Cytosorbents Corporation announced on March 29, 2024, the appointment of Dr. Vincent P. Cappello as Chief Medical Officer. Dr. Cappello previously served as the
• Cytosorbents Corp Files 8-K on Financials — 8-K · Mar 15, 2024 Risk: low
  Cytosorbents Corporation filed an 8-K on March 15, 2024, reporting on its results of operations and financial condition as of March 14, 2024. The filing include
• Cytosorbents Corp Files 2023 Annual Report on Form 10-K — 10-K · Mar 15, 2024 Risk: medium
  Cytosorbents Corp (CTSO) filed a Annual Report (10-K) with the SEC on March 15, 2024. Cytosorbents Corp filed its 10-K report for the fiscal year ending Decembe

Risk Profile

Risk Assessment: Of CTSO's 47 recent filings, 6 were flagged as high-risk, 10 as medium-risk, and 31 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Cytosorbents CORP's most recent 10-K filing (Mar 30, 2026):

• Revenue: $60.6 million
• Net Income: $X
• EPS: $X
• Debt-to-Equity: X.X
• Cash Position: $X
• Operating Margin: X%
• Total Assets: $X
• Total Debt: $X

Key Executives

• Dr. Phillip P. Chan
• Ms. Amy E. Smith
• Dr. Vincent P. Cappello

Industry Context

The critical care and extracorporeal blood purification market is characterized by a focus on improving patient outcomes in life-threatening conditions. Companies are developing advanced technologies to remove toxins, inflammatory mediators, and specific drugs from the bloodstream. Key trends include the increasing use of blood purification in sepsis, organ failure, and post-operative complications, as well as the development of targeted therapies for specific drug removal.

Top Tags

financial-reporting (7) · financials (6) · 8-K (5) · disclosure (5) · 8-k (4) · filing (4) · corporate-filing (4) · sec-filing (4) · corporate-governance (4) · 10-Q (4)

Key Numbers

• Aggregate market value of common stock held by non-affiliates: $60.6 million — as of June 30, 2025, indicating company size
• Outstanding shares of common stock: 62.7 million — as of March 20, 2026
• Countries where CytoSorb is distributed: 70 — demonstrates international reach
• Cumulative CytoSorb devices used: 300,000 — highlights product adoption
• Initial estimated total addressable market for DrugSorb-ATR: $300 million — represents significant revenue potential
• Long-term estimated total addressable market for DrugSorb-ATR: $1 billion — shows growth potential with additional indications
• FDA Breakthrough Device Designations for DrugSorb-ATR: 2 — indicates FDA recognition of potential clinical benefit
• Date of initial De Novo medical device application submission for DrugSorb-ATR: September 2024 — key regulatory milestone
• Date De Novo application accepted for substantive review: October 2024 — progress in regulatory approval process
• Annual patients on Brilinta needing urgent cardiovascular surgery in U.S. and Canada: 60,000 — target patient population for DrugSorb-ATR
• Net Loss (9 months ended Sep 30, 2025): $2.70M — Significantly improved from $13.15M in 2024, largely due to foreign currency gains.
• Net Loss (3 months ended Sep 30, 2025): $3.17M — Increased from $2.77M in the prior-year quarter.
• Revenue (9 months ended Sep 30, 2025): $27.83M — Increased from $26.44M in the prior-year period.
• Revenue (3 months ended Sep 30, 2025): $9.49M — Increased from $8.61M in the prior-year quarter.
• Cash, cash equivalents, and restricted cash (as of Sep 30, 2025): $9.1M — Raises substantial doubt about the company's ability to continue as a going concern.

Related Companies

FMS

Frequently Asked Questions